Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6934190 | 0.84 | KDM4E (0.35) | ACACBLMNAKDM4EHPGDHSD17B10 | |
| SCHEMBL6556019 | 0.72 | PARP1 (0.50) | LMNAKDM4EHPGDHSD17B10MAPT | |
| SCHEMBL18196600 | 0.70 | HPGD (0.42) | LMNAKDM4EHPGDHSD17B10MAPT | |
| SCHEMBL11708040 | 0.68 | CYP1A2 (0.62) | CYP1A2MEN1KMT2A | |
| Oxalic Acid SCHEMBL11719164 | 0.67 | POLB (0.48) | LMNAKDM4EMAPTPOLB | |
| SCHEMBL5200399 | 0.66 | MTNR1A (0.47) | KDM4EHPGDHSD17B10MAPTMTNR1A | |
| SCHEMBL28471767 | 0.65 | ACKR3 (0.39) | PRMT5 | |
| SCHEMBL28469182 | 0.64 | ACKR3 (0.45) | PRMT5 | |
| SCHEMBL11715311 | 0.64 | DHCR7 (0.49) | MAPTMEN1KMT2A | |
| SCHEMBL11709331 | 0.64 | KCNH2 (0.50) | CYP1A2MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040132707-A1 | Catecholate beta-lactam conjugates, method for producing the same and the use thereof | GRUENENTHAL GMBH (DE) | 2004-07-08 | — | — | US | disclosed |
| WO-2002085841-A2 | SUBSTITUTED CATECHOL DERIVATIVES DERIVED FROM POLYBASIC SECONDARY AMINO ACIDS, METHOD FOR PRODUCTION AND USE THEREOF | Grünenthal GmbH (DE) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132707-A1 | Catecholate beta-lactam conjugates, method for producing the same and the use thereof | COMT, CAT, SLC7A11 | ACACB 1512/4885LMNA 4322/4885KDM4E 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.